Tech Center 1600 • Art Units: 1633 1645 1647
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18312653 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | Non-Final OA | Eli Lilly and Company |
| 18455028 | IMMUNE CELL FUNCTION | Non-Final OA | Kite Pharma, Inc. |
| 18330962 | METHODS OF PREPARING LYMPHOCYTES FOR CELL THERAPY | Non-Final OA | Kite Pharma, Inc. |
| 18279848 | PERSONALIZED REDIRECTION AND REPROGRAMMING OF T CELLS FOR PRECISE TARGETING OF TUMORS | Non-Final OA | The General Hospital Corporation |
| 18233733 | ENGINEERED PICOBODY TO ALPHA SYNUCLEIN | Non-Final OA | Qatar Foundation for Education, Science and Community Development |
| 18455544 | COMBINATION THERAPY OF SOLID TUMORS USING CHIMERIC ANTIGEN RECEPTOR CELLS REPRESENTING ADAPTIVE AND INNATE IMMUNITY | Non-Final OA | Regen Biopharma, Inc. |
| 18547627 | METHODS FOR EXPANDING REGULATORY T CELLS | Non-Final OA | KSQ THERAPEUTICS, INC. |
| 18451415 | T CELL RECEPTORS AND FUSION PROTEINS THEREOF | Non-Final OA | Immunocore Ltd |
| 18447152 | METHOD FOR INDUCING RESOLUTIVE MACROPHAGE AND USES THEROF | Non-Final OA | SHIFTBIO INC. |
| 18311474 | STIMULATION OF OVARIAN FUNCTION SUBSEQUENT TO CHEMOTHERAPY AND/OR RADIATION THERAPY USING NATURAL KILLER CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17976601 | HYDROGEL PARTICLES AS FEEDER CELLS AND AS SYNTHETIC ANTIGEN PRESENTING CELLS | Non-Final OA | Slingshot Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy